

**Skyrizi (risankizumab-rzaa)**  
**Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit  
Phone: 877-228-7909 Fax: 800-424-7640

**MEMBER'S LAST NAME:** \_\_\_\_\_ **MEMBER'S FIRST NAME:** \_\_\_\_\_

**Instructions:** Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

☐ **URGENT**

MEMBER INFORMATION		
LAST NAME:		FIRST NAME:
PHONE NUMBER:		DATE OF BIRTH:
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
PATIENT INSURANCE ID NUMBER:		

☐ MALE ☐ FEMALE HEIGHT (IN/CM): \_\_\_\_\_ WEIGHT (LB/KG): \_\_\_\_\_ ALLERGIES: \_\_\_\_\_

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: [PRIMETHERAPEUTICS.COM/NOPP](https://www.primetherapeutics.com/nopp)

**PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):** \_\_\_\_\_

**AUTHORIZED REPRESENTATIVE'S PHONE NUMBER:** \_\_\_\_\_

PRESCRIBER INFORMATION	
LAST NAME:	FIRST NAME:
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:
NPI NUMBER:	DEA NUMBER:
PHONE NUMBER:	FAX NUMBER:
STREET ADDRESS:	
CITY:	STATE: ZIP CODE:
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
<input type="checkbox"/> NEW THERAPY		<input type="checkbox"/> RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:
DURATION OF THERAPY (SPECIFIC DATES):			

*Continued on next page.*

**Skyrizi (risankizumab-rzaa)**  
**Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit  
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: \_\_\_\_\_ MEMBER'S FIRST NAME: \_\_\_\_\_

<b>1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION?</b> <input type="checkbox"/> YES (if yes, complete below) <input type="checkbox"/> NO		
<b>MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):</b>	<b>DURATION OF THERAPY (SPECIFY DATES):</b>	<b>RESPONSE/REASON FOR FAILURE/ALLERGY:</b>
<b>2. LIST DIAGNOSES:</b>		<b>ICD-10:</b>
<input type="checkbox"/> Plaque psoriasis <input type="checkbox"/> Psoriatic Arthritis <input type="checkbox"/> Crohn's Disease <input type="checkbox"/> Ulcerative Colitis  <input type="checkbox"/> Other Diagnosis _____ ICD-10 Code(s): _____		
<b>3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.</b>		
<b>Clinical information:</b> <u><b>Initial Request for all diagnosis:</b></u> Is drug being used as part of a clinical trial? <input type="checkbox"/> Yes <input type="checkbox"/> No  Will the patient be using Skyrizi concurrently with another biologic or other immunomodulatory agents ? <input type="checkbox"/> Yes <input type="checkbox"/> No  Has the patient had a 3-month trial and inadequate response to the biosimilar for Humira-adalimumab-aacf? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>*Must provide documentation, including trial dates.</i>  Does patient have a absolute contraindication to the biosimilar for the biosimilar for Humira-adalimumab-aacf? <input type="checkbox"/> Yes <input type="checkbox"/> No Please submit documentation.  Has the patient tried and had an inadequate response to a 4- month trial of the <u>biosimilar</u> for Stelara-Otulfi(ustekinumb-aauz)? <input type="checkbox"/> Yes <input type="checkbox"/> No Please submit documentation.  Does patient have a absolute contraindication to the biosimilar for <u>Stelara-Otulfi(ustekinumb-aauz)</u> ? <input type="checkbox"/> Yes <input type="checkbox"/> No Please submit documentation.  <u><b>Initial Request for Plaque Psoriasis:</b></u> Is prescriber a dermatologist? <input type="checkbox"/> Yes <input type="checkbox"/> No  Does the patient have plaques covering at least 10% of their body surface area (BSA) or less than 10% of BSA with involvement of palms, soles, head and neck, or genitalia which cause disruption of normal activities? <input type="checkbox"/> Yes <input type="checkbox"/> No  Has the patient had an inadequate response to topical therapy (e.g., corticosteroids, anthralin, calcipotriene, tazarotene)? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>*Must provide documentation, including trial dates.</i>  Select if the patient has had a trial and inadequate response to the following phototherapy options: <input type="checkbox"/> Psoralens with UVA light (PUVA ) <input type="checkbox"/> UVB with coal tar  Select if the patient has had a trial and inadequate response to the following systemic therapies:		

**Skyrizi (risankizumab-rzaa)**  
**Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit  
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: \_\_\_\_\_ MEMBER'S FIRST NAME: \_\_\_\_\_

☐ Acitretin    ☐ Cyclosporine    ☐ Methotrexate    ***\*Must provide documentation, including trial dates.***

Does the patient have documentation of a contraindication to all oral systemic therapies?    ☐ Yes    ☐ No

***\*Must provide documentation.***

**Initial Request for Psoriatic Arthritis:**

Is prescriber a dermatologist or rheumatologist?    ☐ Yes    ☐ No

Will the patient be using Skyrizi concurrently with another biologic or other immunomodulatory agents ?    ☐ Yes    ☐ No

Does the patient have documented active disease?    ☐ Yes    ☐ No ***\*Must provide documentation***

Has the patient had a trial and failed previous therapy with oral disease modifying anti-rheumatic agents (DMARDs, e.g., methotrexate, sulfasalazine (Azulfidine), leflunamide(Arava), or cyclosporine)?    ☐ Yes    ☐ No

***\*Must provide documentation and dates of therapy***

**For Initial Request for Crohn's disease, also answer the following:**

Select if the patient has tried and had an inadequate response, intolerance, or contraindication to the following systemic therapies:

- ☐ Glucocorticoid therapy
- ☐ Methotrexate
- ☐ Azathioprine
- ☐ 6-mercaptopurine
- ☐ 5-ASA/mesalamine

Please provide supporting documentation, including which agent(s) have been tried and trial dates:

\_\_\_\_\_

**Initial Request for Ulcerative Colitis:**

Is the prescriber a gastroenterologist?    ☐ Yes    ☐ No

Will the patient be using Skyrizi concurrently with another biologic or other immunomodulatory agents ?    ☐ Yes    ☐ No

Select if the patient has tried and had an inadequate response, intolerance, or contraindication to the following systemic therapies:

- ☐ Glucocorticoid therapy
- ☐ Methotrexate
- ☐ Azathioprine
- ☐ 6-mercaptopurine

Please provide supporting documentation, including which agent(s) have been tried and trial dates:

\_\_\_\_\_

**Renewal Requests:**

Is the prescriber one of the below?    ☐ Yes    ☐ No

- ☐ gastroenterologist
- ☐ dermatologist
- ☐ rheumatologist

Will the patient be using Skyrizi concurrently with another biologic or other immunomodulatory agents ?    ☐ Yes    ☐ No

**Skyrizi (risankizumab-rzaa)**  
**Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit  
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: \_\_\_\_\_ MEMBER'S FIRST NAME: \_\_\_\_\_

**Is the patient continuing to have a positive clinical response?** ☐ Yes ☐ No ***\*Must provide documentation***

**Please note:** Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

**ATTESTATION:** I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

**Prescriber Signature or Electronic I.D. Verification:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**CONFIDENTIALITY NOTICE:** The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

**FAX THIS FORM TO: 800-424-7640**

**MAIL REQUESTS TO:** Prime Therapeutics Management Prior Authorization Program

Attn: CP – 4201

P.O. Box 64811

St. Paul, MN 55164-0811